Vaccines and pharmaceuticals for animal health

Intervacc

Intervacc is a Swedish company which develops vaccines against infectious bacteria, focused on the animal health care market. According to Intervacc’s management, the technology platform can be used to develop vaccines for any bacterial species, in principle. The company’s subsidiary, Nordvacc, distributes veterinary vaccines across the Nordic and Baltic regions, as well as in the Netherlands. Intervacc has been listed on Nasdaq First North since 2017.

Financials

INTERVACC

SEKm 2017 2018 2019
Sales 48 39 13
Sales growth (%) -13,6 -19,4 -67,7
EBITDA -7 -11 -18
EBITDA margin (%) -15 -28,7 -142,7
EBIT adj -14 -18 -24
EBIT adj margin (%) -28,5 -45,4 -194,4
Pretax profit -14 -18 -24
EPS rep -0,79 -0,43 -0,65
EPS growth (%) -29,5 45,3 -49,2
EPS adj -0,79 -0,43 -0,65
DPS 0 0 0
EV/EBITDA (x) -14,7 -20,2 -14
EV/EBIT adj (x) -7,7 -12,8 -10,2
P/E (x) -9,3 -17,2 -11,5
P/E adj (x) -9,3 -17,2 -11,5
EV/sales (x) 2,2 5,8 19,9
FCF yield (%) -26,8 -6,8 -8,8
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 1,8 5 1,7

Main shareholders

Intervacc

Main shareholders Share capital % Voting shares % Verified
K Janzon Holding AB 10.1 % 10.1 % 2 Feb 2018
Thomas Eklund 8.9 % 8.9 % 30 Sep 2018
Avanza Pension 7.1 % 7.1 % 30 Sep 2018
Knutsson Holdings AB 5.6 % 5.6 % 30 Sep 2018
Lyftet Holding BV 5.3 % 5.3 % 30 Sep 2018
Rothesay Ltd 5.0 % 5.0 % 31 Mar 2018
N.R Bergman Holding AB 4.2 % 4.2 % 30 Sep 2018
Fredrik Lundgren 3.7 % 3.7 % 30 Sep 2018
Björn Sjöstrand 3.3 % 3.3 % 30 Sep 2018
Nordnet Pensionsförsäkring 3.0 % 3.0 % 30 Sep 2018

Insider list

Intervacc

Name
Kenneth Jansson
Kenneth Jansson
Kenneth Jansson
Show More